溶酶体在急性髓系白血病中:潜在的治疗靶点?
该综述概述溶酶体在细胞稳态、代谢与免疫调控中的多重功能及其在恶性肿瘤中的作用,讨论溶酶体在造血细胞中的相关性以及靶向溶酶体治疗急性髓系白血病(AML)的多种潜在策略。
要点
- 溶酶体不仅是降解细胞大分子的细胞器,还调控营养信号、能量代谢与免疫。
- AML基因组特征已被广泛表征,但除分化治疗外少有靶向治疗可实现长期治愈。
- 靶向溶酶体可能为AML提供低强度、更可耐受的新型治疗思路。
核心结论
- 溶酶体作为细胞稳态的关键调控者,靶向溶酶体是AML潜在的新型治疗方向。
研究设计与样本
- 综述类文章,检索范围未在摘要中报告。
主要发现
- 溶酶体处于分解代谢与合成代谢通路的交叉点,参与细胞运输、营养信号、能量代谢和免疫调节。
- AML是一种侵袭性血液肿瘤,尤其老年患者生存概率低,除分化治疗外少有靶向治疗能实现长期治愈。
关键数值与推荐
- 文中汇总的溶酶体功能与AML靶向策略的标准与数值未在摘要中报告。
临床怎么用
- 为AML尤其是需要低强度治疗的患者提供靶向溶酶体的潜在治疗思路。
局限性
- 摘要未报告综述的检索范围与纳入标准,无法评估证据覆盖的全面性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lysosomes, since their discovery, have been primarily known for degrading cellular macromolecules. However, in recent studies, they have begun to emerge as crucial regulators of cell homeostasis. They are at the crossroads of catabolic and anabolic pathways and are intricately involved in cellular trafficking, nutrient signaling, energy metabolism, and immune regulation. Their involvement in such essential cellular functions has renewed clinical interest in targeting the lysosome as a novel way to treat disease, particularly cancer. Acute myeloid leukemia (AML) is an aggressive blood cancer with a low survival probability, particularly in older patients. The genomic landscape of AML has been extensively characterized but few targeted therapies (with the exception of differentiation therapy) can achieve a long-term cure. Therefore, there is an unmet need for less intensive and more tolerable therapeutic interventions. In this review, we will give an overview on the myriad of functions performed by lysosomes and their importance in malignant disease. Furthermore, we will discuss their relevance in hematopoietic cells and different ways to potentially target them in AML.
引用
- Rafiq S, McKenna SL, Muller S, et al. Lysosomes in acute myeloid leukemia: potential therapeutic targets? Leukemia. 2021. PMID: 34462526. doi:10.1038/s41375-021-01388-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。